Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track STTK with free AI briefings, catalyst countdowns, and dilution alerts.

STTK · Shattuck Labs, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$197.3M Cash on Hand
42.8mo Cash Runway
Follow STTK by email Get an email when STTK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about STTK, unsubscribe in one click. Privacy

📣 What STTK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SL-325 Crohn's Disease Phase 2 · NCT07753850 Recruiting
Drug: SL-172154 Cutaneous Squamous Cell Carcinoma Phase 1 · NCT04502888 Terminated
Mirvetuximab Platinum-resistant Ovarian Cancer Phase 1 · NCT05483933 Completed
Pegylated Liposomal Doxorubicin Hydrochloride Platinum-resistant Ovarian Cancer Phase 1 · NCT05483933 Completed
SIRPa-Fc-CD40L Fusion Protein SL-172154 Acute Myeloid Leukemia Phase 1 · NCT05275439 Terminated
ARC Fusion Protein SL-279252 Squamous Cell Carcinoma of the Head and Neck Phase 1 · NCT03894618 Completed

Also used in these trials (approved or third-party drugs, not STTK's own candidates): Azacitidine, Venetoclax.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

STTK holds $197.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.8M/quarter from operations, an estimated runway of 42.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when STTK files for a raise →

👥 Who Owns STTK

Insiders 4.7% Institutions (149 holders) 79.8% Public and other holders 15.5%
HolderTypeShares% of sharesAs of
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 13,432,540 13.19% 2026-06-30
Redmile Group, LLC Institution (13G, 5%+) 10,019,421 9.84% 2026-07-15
BlackRock, Inc. Institution (13G, 5%+) 5,339,458 5.24% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 5,000,033 4.91% 2026-06-10
Taylor Schreiber
Chief Executive Officer, Director · +1.55M options
Insider 2,732,972 2.68% 2026-05-12
ORBIMED ADVISORS LLC
Director · +5.30M options
Insider 1,051,021 1.03% 2026-06-11
Mona Ashiya
Director · +5.45M options
Includes shares also reported by ORBIMED ADVISORS LLC, counted once
Insider 1,051,021 1.03% 2026-06-11
Clay B Siegall
Director · +81,000 options
Insider 318,608 0.31% 2026-06-09
Andrew R Neill
Chief Financial Officer · +549,800 options
Insider 292,251 0.29% 2026-05-12
Arundathy N. Pandite
Chief Medical Officer · +487,800 options
Insider 136,219 0.13% 2026-06-30
Abhinav A. Shukla
Chief Technical Officer · +329,640 options
Insider 98,533 0.10% 2026-07-02
Stephen Stout
General Counsel, Corporate Secretary and · +351,400 options
Insider 93,366 0.09% 2026-05-15

Share count 101,842,552 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full STTK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for STTK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.